An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy

计划入组 24 人 · 首次发布于 2026 年 7 月 10 日

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

计划入组 21 人 · 首次发布于 2017 年 10 月 16 日

β-globin Restored Autologous HSC in β-thalassemia Major Patients

计划入组 2 人 · 首次发布于 2019 年 12 月 19 日

Obinutuzumab(Gazyva, Gazyvaro)

Rx

Obinutuzumab beta

β-Hydroxythiofentanyl

C₂₀H₂₆N₂O₂S

Obinutuzumab β (MIL62) Shows 93.1% Relapse Risk Reduction in Phase 3 Trial for AQP4-IgG+ NMOSD

Acalabrutinib, Venetoclax, and Obinutuzumab Show Promise in Frontline CLL Treatment

Obinutuzumab Shows Promise in Treating Proliferative Lupus Nephritis